Antibody-drug conjugates taking center stage in oncology

antibody_drug_conjugate_large

An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's (NYSE: PFE) newly-announced $43 billion  takeover of Seagen (Nasdaq: SGEN).

An ADC is typically composed of a monoclonal antibody (MAb) covalently attached to a cytotoxic drug (payload) via a chemical linker (which helps to increase tumor specificity and reduce off-target effects. In 2021, the ADC market was worth $4 billion and is forecast to rise to $13.13 billion by 2030, delivering a CAGR 2021-2030 of 14.12% (Figure 1).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology